Sriram Yennu, MD
Internal Medicine · Houston, TXNPI 1649361379
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (46.0%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Pfizer accounts for 96.5% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2020 at $10,325 and has fallen 89.8% since, to $1,050 in 2021. Among internal medicine clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 12 payments — averaging $1110.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$13K
- Astellas Pharma Inc$350
- Ipsen Biopharmaceuticals, Inc$120
Across 32 payments — averaging $12,376 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$239K
- Helsinn Healthcare SA$157K
What the payments were for
- Consulting fees$5,60042%
- Speaking & faculty fees$6,12546%
- Travel & lodging$1,1989%
- Food & beverage$4023%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 10 | $12,854 |
| Astellas Pharma Inc | 1 | $350 |
| Ipsen Biopharmaceuticals, Inc | 1 | $120 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOMATULINE DEPOT$120
- ONIVYDE$120
How this compares
$13,324 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fentanyl | 24 | $2,266 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 29 | $970 |
| Morphine Sulfate ErMorphine Sulfate | 18 | $622 |
| Hydromorphone Hcl | 26 | $536 |
| Oxycodone Hcl | 26 | $384 |
| Morphine Sulfate | 16 | $351 |
| Mirtazapine | 25 | $330 |
| Methylphenidate Hcl | 19 | $319 |
| Duloxetine Hcl | 21 | $276 |
| Olanzapine | 21 | $260 |
| Gabapentin | 14 | $180 |
| Metoclopramide Hcl | 16 | $138 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Houston
- Hussein TawbiHouston$365K
- Hans LeeHouston$327K
- Tapan KadiaHouston$311K
- Nitin JainHouston$281K
- Krina PatelHouston$255K
- Nicholas ShortHouston$247K
- Naveen PemmarajuHouston$230K
- Mariana Chavez MacgregorHouston$188K
- Shumei KatoHouston$180K
- Sukhdeep BasraHouston$168K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.